Javelin Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Javelin Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Javelin Pharmaceuticals: 9 sponsored US clinical trials, none currently recruiting.

Javelin Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pain, Postoperative, with 1 trials.

Top-decile sponsor footprint

Javelin Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 1

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
COMPLETED Phase 1

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

NCT00662883
COMPLETED Phase 1

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

NCT00548678
COMPLETED Phase 1

Study to Assess Effects of Age, Weight, and Body Composition on the Pharmacokinetics of IV Diclofenac Sodium

NCT00509743
COMPLETED Phase 1

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

NCT00520169
COMPLETED Phase 1

Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium

NCT00474136
COMPLETED Phase 1

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine)

NCT00474799
COMPLETED Phase 3

Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery

NCT00448110
COMPLETED Phase 3

Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery

NCT00390039

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 3 2

Therapeutic Areas

Pain, Postoperative 1
Healthy 1

How the Javelin Pharmaceuticals early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Pain, Postoperative (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Javelin Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Javelin Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Javelin Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Javelin Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Javelin Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Javelin Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Javelin Pharmaceuticals or any single study.

  • None of Javelin Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pain, Postoperative is the condition Javelin Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pain, Postoperative trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Javelin Pharmaceuticals pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.